HomeCompareNXEN vs PLD

NXEN vs PLD: Dividend Comparison 2026

NXEN yields 2000000.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NXEN wins by $4.879226400974806e+39M in total portfolio value
10 years
NXEN
NXEN
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full NXEN calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — NXEN vs PLD

📍 NXEN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXENPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXEN + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXEN pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXEN
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, NXEN beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXEN + PLD for your $10,000?

NXEN: 50%PLD: 50%
100% PLD50/50100% NXEN
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

NXEN
No analyst data
Altman Z
-2078.6
Piotroski
1/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXEN buys
0
PLD buys
0
No recent congressional trades found for NXEN or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXENPLD
Forward yield2000000.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$4.879226400974806e+39M$5.91M
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$4,750,725.19
Total dividends collected$4.879195005460081e+39M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: NXEN vs PLD ($10,000, DRIP)

YearNXEN PortfolioNXEN Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,241$540.96+$200.00MNXEN
2$3,738,731,768,458$3,738,517,757,009.35$13,019$991.13+$3738731.76MNXEN
3$65,315,062,866,930,490$65,311,062,423,938,240.00$15,801$1,870.97+$65315062866.91MNXEN
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$20,609$3,701.21+$1066400830062625.00MNXEN
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$29,919$7,867.97+$16272182796453826560.00MNXEN
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$50,631$18,617.74+$2.3205424011366188e+23MNXEN
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$105,528$51,352.20+$3.0927990661046884e+27MNXEN
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$287,364$174,449.42+$3.8524105697352695e+31MNXEN
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$1,081,760$774,280.77+$4.484688260147987e+35MNXEN
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$5,908,209$4,750,725.19+$4.879226400974806e+39MNXEN

NXEN vs PLD: Complete Analysis 2026

NXENStock

Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

Full NXEN Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this NXEN vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXEN vs SCHDNXEN vs JEPINXEN vs ONXEN vs KONXEN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.